OpenAI CEO Sam Altman’s new brain-computer interface startup, Merge Labs, is being spun out of the Los Angeles–based nonprofit Forest Neurotech, according to a source with direct knowledge of the ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

I remember when I was a new teacher and the principal raved about this odd-sounding tech tool called “mail merge.” I probably would have ignored the rest but he kept referring to it as a time saver ...

Merging disk partitions is useful to optimize disk space, especially when managing multiple partitions on a single disk. However, Windows Disk Management can only ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community. Issues are used to track todos, bugs, feature requests, and more.

There's no limit to the number of Google accounts one can have. As a result, many of us have created more than one over the years. You may have signed up for your first account in college and opened a ...

Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...

The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...